publicMHRA · United Kingdom · Updated Aug 18, 2026
MHRA Clarifies Regulatory Pathways for Microbiome-Based Medicinal Products
Developers of MBMPs must align their safety assessment protocols with the MHRA's expectations and are encouraged to engage with the MHRA early to establish appropriate regulatory strategies.
Literature SurveillanceCountry ComplianceRegulatory Intelligence Lead
SOP Impact2 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead, QPPV
verifiedRegulatory action: Notice / Position Paper
Read impact briefarrow_forward